CD98 is the marker of cancer stem cell and radioresistance
| Project/Area Number |
15K20177
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Multi-year Fund |
|---|
| Research Field |
Otorhinolaryngology
|
|---|
| Research Institution | Akita University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2015-04-01 – 2018-03-31
|
| Project Status |
Completed (Fiscal Year 2017)
|
| Budget Amount *help |
¥3,120,000 (Direct Cost: ¥2,400,000、Indirect Cost: ¥720,000)
Fiscal Year 2017: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2016: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2015: ¥1,170,000 (Direct Cost: ¥900,000、Indirect Cost: ¥270,000)
|
|---|
| Keywords | CD98hc / 癌幹細胞 / 放射線耐性 / 頭頸部扁平上皮癌 / 頭頚部扁平上皮癌 / 放射線感受性 / CD98 / CD326 |
|---|
| Outline of Final Research Achievements |
In head and neck cancer, failure in radiotherapy causes subsequent life prognosis failure. 60 Gy radiation was applied to five head and neck squamous cell carcinoma cell lines HO-1-u-1, Sa 3, HSC 2, HSC 3, HSC 4. Overexpression of CD98hc was confirmed in all cells, and Colony forming ability and migration ability were enhanced. When only CD98hc positive cells were extracted, it was found that Colony forming ability, invasion ability, and adhesion ability were enhanced as compared with the negative cells. Furthermore, it had high tumorigenicity in animal experiments. The amino acid transporter CD98hc will be a target for cancer therapy.
|
Report
(4 results)
Research Products
(10 results)
